Silo Pharma, Inc. (SILO) Income Statement
SILO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSILO revenue and net income
Where SILO's revenue goes
2025Each bar shows an amount and its share of revenue. SILO kept −5,863.5% of revenue as net income.
SILO profit margins
SILO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | +12.0% | — |
| Gross profit | −1,328.4% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SILO quarterly EPS vs estimates
Silo Pharma beat the analyst EPS estimate in 0 of the last 6 quarters. Next report: November 12, 2026.
SILO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72,102 | $72,102 | $72,102 | $72,102 | $71,264 | $40,923 | $40,569 | $0 | $847,407 | $0 |
| Cost of revenue | $886,057 | $5,838 | $5,838 | $5,838 | $5,004 | $176,126 | $27,387 | $17,550 | $0 | $669,480 |
| Gross profit | −$813,955 | $66,264 | $66,264 | $66,264 | $66,260 | −$135,203 | $13,182 | −$17,550 | $847,407 | −$669,480 |
| Research & development | $2.2M | $2.4M | $845,092 | $1.3M | $693,910 | $26,250 | $63,465 | — | — | — |
| Sales, general & admin | $2.1M | $2.4M | $3.1M | $2.4M | $2.3M | $2.2M | $864,180 | $459,830 | $313,371 | $300,994 |
| Total operating expenses | $3.5M | $4.8M | $3.9M | $3.7M | $2.8M | $2.2M | $943,585 | $459,830 | $490,871 | $443,494 |
| Operating income | −$4.3M | −$4.7M | −$3.9M | −$3.6M | −$2.7M | −$2.2M | −$930,403 | −$594,242 | −$470,388 | −$393,658 |
| Interest income | $193,912 | $333,165 | $361,014 | $72,637 | $1,210 | $11,543 | $12,196 | $4,218 | $20,483 | $49,836 |
| Interest expense | $37,302 | $5,084 | $4,869 | $2,199 | $3,036 | $269,267 | $62,928 | $4,218 | $20,483 | $49,836 |
| Income before taxes | −$4.2M | −$4.4M | −$3.6M | −$3.9M | $4.2M | −$2.7M | −$1.0M | −$969,463 | $356,536 | −$1.1M |
| Income taxes | — | — | $69,600 | $1,163 | $24,876 | $92,348 | $34,792 | −$513,851 | −$62,910 | — |
| Net income | −$4.2M | −$4.4M | −$3.7M | −$3.9M | $3.9M | −$3.0M | −$1.0M | −$969,463 | $356,536 | −$1.1M |
| EBITDA | −$4.2M | −$4.4M | −$3.6M | −$3.9M | $4.2M | −$2.4M | −$950,366 | −$951,914 | $356,536 | $325,658 |
| EPS (diluted) | −$4.76 | −$1.40 | −$9.16 | −$1.65 | $2.80 | −$0.09 | −$0.05 | −$0.03 | −$0.01 | −$0.01 |
| Gross margin | −1,128.9% | 91.9% | 91.9% | 91.9% | 93.0% | −330.4% | 32.5% | — | 100.0% | — |
| Operating margin | −5,937.0% | −6,526.4% | −5,347.4% | −5,031.3% | −3,851.0% | −5,380.2% | −2,293.4% | — | −55.5% | — |
| Net margin | −5,863.5% | −6,092.6% | −5,132.6% | −5,420.9% | 5,477.9% | −7,422.5% | −2,497.7% | — | 42.1% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $18,026 | $18,026 | $18,025 | $18,025 | $18,026 | $18,026 | $18,025 | $18,025 | $18,026 | $18,026 | $18,025 |
| Cost of revenue | $2,938 | $266,258 | $20,689 | $20,687 | $1,459 | $1,460 | $399,863 | $1,459 | $1,459 | $1,460 | $1,460 | $1,459 |
| Gross profit | −$2,938 | −$248,232 | −$2,663 | −$2,662 | $16,566 | $16,566 | −$381,837 | $16,566 | $16,566 | $16,566 | $16,566 | $16,566 |
| Research & development | $298,418 | $1.0M | $306,005 | $543,615 | $717,247 | $593,962 | $1.1M | $517,548 | $392,824 | $318,240 | $336,965 | $174,495 |
| Sales, general & admin | $630,531 | $333,163 | $477,856 | $605,189 | $547,870 | $516,725 | $754,199 | $509,073 | $626,516 | $577,839 | $843,325 | $615,469 |
| Total operating expenses | $928,949 | $1.3M | $783,861 | $1.1M | $1.3M | $1.1M | $1.5M | $1.0M | $1.0M | $896,079 | $1.2M | $789,964 |
| Operating income | −$928,949 | −$1.6M | −$786,524 | −$1.2M | −$1.2M | −$1.1M | −$1.9M | −$1.0M | −$1.0M | −$879,513 | −$1.2M | −$773,398 |
| Interest income | $39,155 | $38,718 | $42,563 | $44,604 | $44,917 | $61,828 | $83,006 | $84,940 | $77,042 | $88,177 | $108,380 | $116,178 |
| Interest expense | $2,865 | $3,373 | $32,702 | $886 | $1,648 | $2,066 | $274 | $1,081 | $1,859 | $1,870 | $273 | $1,078 |
| Income before taxes | −$832,829 | −$1.6M | −$881,530 | −$1.1M | −$1.2M | −$1.0M | −$1.7M | −$928,814 | −$931,779 | −$801,667 | −$1.1M | −$660,160 |
| Income taxes | — | — | — | — | — | — | — | — | — | — | $69,600 | −$115,100 |
| Net income | −$832,829 | −$1.6M | −$881,530 | −$1.1M | −$1.2M | −$1.0M | −$1.7M | −$928,814 | −$931,779 | −$801,667 | −$1.1M | −$660,160 |
| EBITDA | −$988,779 | −$1.6M | −$845,891 | −$1.1M | −$1.2M | −$1.0M | −$1.8M | −$924,641 | −$929,920 | −$799,797 | −$995,011 | −$659,082 |
| EPS (diluted) | −$0.76 | −$1.80 | — | −$0.12 | −$0.41 | −$0.23 | −$0.60 | −$0.22 | −$0.31 | −$0.28 | −$5.40 | −$3.15 |
| Gross margin | — | −1,377.1% | −14.8% | −14.8% | 91.9% | 91.9% | −2,118.3% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% |
| Operating margin | — | −8,846.4% | −4,363.3% | −6,388.2% | −6,926.8% | −6,069.7% | −10,414.2% | −5,603.6% | −5,563.2% | −4,879.1% | −6,455.8% | −4,290.7% |
| Net margin | — | −9,137.5% | −4,890.3% | −6,160.5% | −6,681.2% | −5,721.9% | −9,600.7% | −5,152.9% | −5,169.4% | −4,447.3% | −6,219.8% | −3,662.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SILO's financial statements (latest annual report filed March 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SILO financial results
In fiscal year 2025 (ended December 31, 2025), Silo Pharma reported revenue of $0.1 million, up 0.0% from the year before. It had a net loss of $4.2 million, a net profit margin of −5,863.5%. Diluted earnings per share came to −$4.76. Over five years revenue grew at an average rate of 12.0% a year.
See the SILO stock overview for the latest quote and news, or the SILO chart for price history and technical indicators.
SILO income statement FAQ
What is Silo Pharma's annual revenue?
Silo Pharma reported total revenue of $0.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 0.0% from $0.1 million the previous year.
Is Silo Pharma profitable?
No. Silo Pharma reported a net loss of $4.2 million in fiscal 2025, a net profit margin of −5,863.5%; its operating margin was −5,937.0%.
What is Silo Pharma's gross margin?
Silo Pharma's gross margin was −1,128.9% in fiscal 2025: for every $100 of revenue, Silo Pharma kept $-1129 after the direct cost of its products and services.
How much does Silo Pharma spend on research and development?
Silo Pharma spent $2.2 million on research and development in fiscal 2025, 2,996.9% of revenue.
How fast is Silo Pharma growing?
Revenue grew 12.0% a year on average over the last five fiscal years, from $0.0 million to $0.1 million.
What are Silo Pharma's earnings per share?
Silo Pharma earned $-4.76 per diluted share in fiscal 2025, compared with $-1.40 a year earlier.
When will Silo Pharma report its next earnings?
Silo Pharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Silo Pharma's fiscal year end?
Silo Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 27, 2026.